When asked about risks, Apogee's CEO identified a lack of focus—not clinical failure—as the primary threat. By concentrating resources on atopic dermatitis, a large but underserved market, the smaller company can execute faster and more effectively than larger, more diffuse competitors like Sanofi and Lilly.

Despite Dupixent's dominance, Apogee's CEO claims the atopic dermatitis market has so much unmet need that new drugs with even limited differentiation are achieving blockbuster status. This suggests the market is expanding to accommodate new entrants, rather than being a zero-sum game of stealing market share.

While smaller trials like KEYNOTE-905 can show dramatic results, they are subject to more statistical noise. Larger, thousand-patient studies like B15 and Niagara, with narrower confidence intervals, are considered closer to the true effect size and provide a more stable foundation for establishing the standard of care.

Instead of running separate Phase 2 and 3 trials, iOnctura plans to "operationally upsize" its current study. This involves keeping the same clinical sites open and transitioning directly into a Phase 3 cohort with new patients, creating a more efficient, faster, and less costly path to potential approval.

Apogee positions its 3- and 6-month dosing as a driver of superior adherence and better long-term outcomes, not just a lifestyle perk. The CEO draws a parallel to the psoriasis market, where less frequent dosing transformed the therapeutic landscape by encouraging more patients to start and stay on therapy.

Despite FDA readiness for a final Phase 3 trial, Connect Biopharma chose to run more Phase 2 studies. They discovered their long-term asthma drug worked in hours, not weeks, and are now pivoting to prove its value in acute, emergency situations, which informs a stronger, more targeted Phase 3 design.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

Contrary to market convention, a trial delay can be a bullish signal. When an independent data monitoring committee (IDMC) recommends adding more patients, as with Bristol's ADEPT-2 study, it implies they've seen a therapeutic signal worth salvaging, potentially increasing the trial's ultimate chance of success.

Experts believe the stark difference in complete response rates (5% vs 30%) between two major ADC trials is likely due to "noise"—variations in patient populations (e.g., more upper tract disease) and stricter central review criteria, rather than a fundamental difference in the therapies' effectiveness.